News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,372 Results
Type
Article (14020)
Company Profile (293)
Press Release (247059)
Section
Business (79722)
Career Advice (164)
Deals (13236)
Drug Delivery (32)
Drug Development (50489)
Employer Resources (34)
FDA (5702)
Job Trends (5146)
News (144749)
Policy (10124)
Tag
Academia (917)
Alliances (21538)
Alzheimer's disease (735)
Approvals (5669)
Artificial intelligence (62)
Bankruptcy (98)
Best Places to Work (4517)
Biotechnology (242)
Breast cancer (62)
Cancer (651)
Cardiovascular disease (52)
Career advice (142)
CAR-T (48)
Cell therapy (162)
Clinical research (39812)
Collaboration (218)
Compensation (91)
COVID-19 (1060)
C-suite (61)
Cystic fibrosis (61)
Data (712)
Diabetes (71)
Diagnostics (1206)
Earnings (29004)
Events (47000)
Executive appointments (169)
FDA (5965)
Funding (227)
Gene editing (53)
Gene therapy (136)
GLP-1 (300)
Government (1095)
Healthcare (6629)
Infectious disease (1093)
Inflammatory bowel disease (91)
IPO (7213)
Job creations (864)
Job search strategy (136)
Layoffs (185)
Legal (1393)
Lung cancer (105)
Manufacturing (71)
Medical device (2602)
Medtech (2603)
Mergers & acquisitions (6111)
Metabolic disorders (218)
Neuroscience (927)
NextGen Class of 2024 (2037)
Non-profit (886)
Northern California (872)
Obesity (123)
Opinion (97)
Parkinson's disease (57)
Patents (48)
People (25039)
Pharmaceutical (48)
Phase I (14001)
Phase II (18523)
Phase III (11757)
Pipeline (254)
Postmarket research (846)
Preclinical (5914)
Radiopharmaceuticals (203)
Rare diseases (152)
Real estate (1430)
Regulatory (8245)
Research institute (937)
Southern California (811)
Startups (1968)
United States (7183)
Vaccines (163)
Weight loss (77)
Date
Today (131)
Last 7 days (591)
Last 30 days (2138)
Last 365 days (20540)
2024 (18447)
2023 (22488)
2022 (26936)
2021 (28031)
2020 (23715)
2019 (16377)
2018 (11891)
2017 (13837)
2016 (11921)
2015 (14412)
2014 (10455)
2013 (7522)
2012 (7565)
2011 (7644)
2010 (7456)
Location
Africa (147)
Asia (16864)
Australia (2860)
California (1982)
Canada (679)
China (152)
Colorado (78)
Connecticut (81)
Europe (36298)
Florida (210)
Georgia (57)
Illinois (123)
Indiana (54)
Kansas (55)
Maryland (290)
Massachusetts (1618)
Michigan (48)
Minnesota (90)
New Jersey (518)
New York (584)
North Carolina (391)
Northern California (872)
Ohio (75)
Pennsylvania (405)
South America (216)
Southern California (811)
Texas (204)
Washington State (207)
261,372 Results for "storm therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
First Patient in STORM-PE RCT Enrolled Evaluating Penumbra’s Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism
Penumbra, Inc. announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE).
November 28, 2023
·
6 min read
Drug Development
Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting
Trefoil Therapeutics today announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the Phase 2 STORM study.
May 8, 2023
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Pharm Country
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m. U.S. Eastern Time.
July 1, 2024
·
4 min read
Business
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.
June 20, 2024
·
6 min read
Policy
FDA Provides Update Regarding Storm Damage at Pfizer Facility in North Carolina
The U.S. Food and Drug Administration is working closely with Pfizer to assess the impact of the damage at Pfizer’s Rocky Mount, North Carolina, facility.
July 21, 2023
·
3 min read
Press Releases
Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
October 30, 2024
·
2 min read
Business
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
October 14, 2021
·
8 min read
Pharm Country
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
BrainStorm Cell Therapeutics Inc announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 11,111,111 shares of the Company’s common stock at a purchase price of $0.36 per share in a registered direct offering.
June 27, 2024
·
5 min read
Drug Development
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
BrainStorm Cell Therapeutics Inc. ment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm’s Phase 3b clinical trial for NurOwn.
June 26, 2024
·
4 min read
1 of 26,138
Next
